Evidence map›Paper›PMID 39611955›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Coseasonal initiation of Artemisia annua sublingual immunotherapy in children and adult patients with allergic rhinoconjunctivitis.

Jin Li, Wei Liu, Yong Jun Xu, Qiang Fu, Ju Liu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Corticosteroids sparing effect of artemisia annua sublingual immunotherapy: A prospective study in pediatric seasonal allergic rhinoconjunctivitis (INCs sparing and efficacy of Artemisia annua SLIT in pediatric SARC).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Trial
  3. Clinical outcomes of 2-yearAsia Pacific allergy · 2026
    Article
  4. Article
  5. [Pediatric thunderstorm asthma in China: epidemiological characteristics and comprehensive management].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin LiDepartment of Otolaryngology, Ordos Central Hospital, No. 23, Yijin Huoluo West Street, Dongsheng District, Ordos, Inner Mongolia, China. lijin6840@sina.com.ORCID http://orcid.org/0009-0002-7131-7534
Wei LiuDepartment of Otolaryngology, Ordos Central Hospital, No. 23, Yijin Huoluo West Street, Dongsheng District, Ordos, Inner Mongolia, China.
Yong Jun XuDepartment of Otolaryngology, Ordos Mongolian Hospital, Ordos, Inner Mongolia, China.
Qiang FuDepartment of Otolaryngology, Ordos Central Hospital, No. 23, Yijin Huoluo West Street, Dongsheng District, Ordos, Inner Mongolia, China.
Ju LiuDepartment of Otolaryngology, Ordos Central Hospital, No. 23, Yijin Huoluo West Street, Dongsheng District, Ordos, Inner Mongolia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate the efficacy and safety of coseasonal initiation of Artemisia annua sublingual immunotherapy (SLIT) for children and adult patients with allergic rhinoconjunctivitis (ARC).

methodsA total of 50 patients (aged 4-60 years) with ARC who visited hospital from July to September 2022 were enrolled and randomly divided into the SLIT (n = 25) and control group (n = 25). Patients in SLIT group received Artemisia annua SLIT and patients in control group only received symptomatic medication. The study continued for 1 year. Four nasal symptom scores, two eye symptom scores, and medication usage of the patients during 2021 (baseline) and 2023 pollen seasons were recorded, as well as adverse events (AEs) during the study.

resultsFinally, 20 patients of SLIT group and 22 patients of control group completed this study. Compared with the baseline, the levels of total rhinoconjunctivitis symptom score (TRSS), total medication score (TMS), and combined symptom and medication score for rhinoconjunctivitis (CSMS-RC) experienced significant reductions after 1 year SLIT. Additionally, these outcomes also decreased significantly in SLIT group when compared with the control group during 2023 pollen season. Especially, there were more patients showed symptoms reduction, medication use decrease, and efficacy improvement in the SLIT group. Notably, no severe AEs were observed throughout the treatment course among patients receiving SLIT.

conclusionsCoseasonal initiating Artemisia annua SLIT demonstrated clinical efficacy and safety for children and adult patients with ARC.

Indexed as

Artemisia annuaConjunctivitis, AllergicRhinitis, AllergicRhinitis, Allergic, SeasonalSublingual ImmunotherapyAdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultAllergic rhinoconjunctivitisArtemisia annuaCoseasonalEfficacySafetySublingual immunotherapy

Identifiers

PMID39611955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.